A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment
Lei Wang, Yong Ke, Qunye He, Pameila Paerhati, Weiliang Zhuang, Yali Yue, Junjun Liu, Jiawei Zhang, Lulu Huang, Qiang Yin, Huifang Zong, Jianwei Zhu, Baohong Zhang
Abstract
These results indicate that the degrader-antibody conjugate is a promising candidate for tumor-specific degradation and effective cancer therapy.
Topics & Concepts
Antibody-drug conjugateConjugateAntibodyCancer researchBRD4MedicineChemistryBromodomainMonoclonal antibodyImmunologyDNAHistoneBiochemistryMathematical analysisMathematicsProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways